Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer Patient-reported outcomes in the PEARL study /

Hasonló tételek

• Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer a phase III randomised controlled trial—PEARL /
  Szerző: Martin M., et al.
  Megjelent: (2021)
• Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
  Szerző: Pascual Javier, et al.
  Megjelent: (2023)
• Capecitabine removal from water using commercial granular activated carbon
  Szerző: Popescu Mina Ionela, et al.
  Megjelent: (2022)
• Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer A Systematic Review and Meta-Analysis /
  Szerző: Bérczi Bálint, et al.
  Megjelent: (2024)
• Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
  Szerző: Zielinski Christoph, et al.
  Megjelent: (2016)